| Exclusion Criteria: | 1) Received immunotherapy for cancer within one month prior to the start of screening.
2) Received >2 doses of previous CP-675,206.
3) Patients previously treated on this protocol.
4) History of, or significant evidence of risk for, chronic inflammatory or autoimmune disease (e.g., Addison's disease, asthma, celiac disease, multiple sclerosis, Graves disease, Hashimoto's thyroiditis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, etc.).
5) Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history.
6) History of autoimmune colitis or other chronic gastrointestinal conditions associated with diarrhea or bleeding, or current acute colitis of any origin.
7) Pregnant or lactating women (see Section 3.1.1, criteria 10).
8) Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol.
9) Diagnosed or suspected brain metastases. Patients with past history of brain metastases but with no radiologic evidence within 12 weeks prior to enter into the protocol will be eligible.
10) Any serious uncontrolled medical disorder or active infection, which would impair their ability to receive study treatment.
11) Coexisting malignancies except for basal or squamous cell carcinoma of the skin. |